March 2015

Home  /  2015  /  March

The Joint Assessment of WP5 Strand A on Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma is now available. Find the Joint Assessment here.